GET DAILY SIGNALSAethlon Medical (AEMD): Examining the Hemopurifier's Role in Addressing Unmet Needs in Cancer
Key Takeaways
- Aethlon Medical, Inc. (AEMD) is a clinical-stage medical device company headquartered in San Diego, California, founded in 1984.
- Its lead product is the Hemopurifier, an investigational blood-filtration device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation.
- The device holds U.S. FDA Breakthrough Device Designation for advanced or metastatic cancer and for life-threatening viruses not addressed by approved therapies.
- As a development-stage company, Aethlon generates no meaningful product revenue and relies on equity financings to fund clinical trials and operations.
Background and Context
Aethlon Medical operates as a small-cap healthcare firm focused on the overlap between medical devices and oncology. Instead of pursuing a traditional drug, the company is developing an extracorporeal blood-purification device aimed at clearing disease-related particles from the bloodstream. I follow AEMD because its Hemopurifier platform targets significant unmet needs in treatment-resistant cancer and serious viral infections, even though the technology is still investigational and not approved for sale.
Company Profile and Operations
Aethlon Medical, Inc. was established in 1984 and is based in San Diego, California. It lists on the Nasdaq Capital Market under the ticker AEMD and is led by Chief Executive Officer and Chief Financial Officer James Frakes. The firm remains compact, employing roughly nine full-time staff as it concentrates on one primary technology platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The core of Aethlon's approach centers on the Hemopurifier, a clinical-stage immunotherapeutic device intended for extracorporeal use with a blood pump. It integrates plasma separation, size exclusion, and affinity binding, relying on a plant-derived lectin resin that attaches to mannose-rich surfaces on enveloped viruses and extracellular vesicles released by solid tumors. These vesicles are linked to cancer spread and resistance to immunotherapies and chemotherapy, making their removal the proposed therapeutic strategy.
Oncology represents the company's main emphasis at present. It is running a safety, feasibility, and dose-finding trial in Australia (AEMD-2022-06) testing the Hemopurifier in patients with advanced solid tumors that have advanced after anti-PD-1 immunotherapies such as Keytruda or Opdivo. Earlier work has also included life-threatening viral infections, including an emergency-use case in the 2014 Ebola outbreak.
Given the investigational status of the Hemopurifier, Aethlon's finances align with those of a pre-revenue biotech or device developer. The company reports essentially no product revenue along with ongoing operating losses and negative cash flow. Operations are funded mainly through equity offerings, warrant exercises, and similar transactions. Regulatory filings indicate that additional capital will be needed to progress clinical programs, with no assurance of eventual profitability.
Market Positioning
Aethlon holds a specialized position in the medical device and oncology fields. Its method of physically extracting tumor-derived extracellular vesicles and enveloped viruses from blood, rather than delivering a pharmaceutical, sets it apart from standard drug developers. This creates what is sometimes viewed as a "pipeline within a single device," with potential applications across oncology, infectious disease, and organ transplantation.
That said, the company competes against numerous cancer immunotherapy and device developers, many with greater resources and more advanced programs. Its standing depends more on clinical trial progress and emerging data than on near-term sales.
Investor Interest in AEMD
Attention centers on the Hemopurifier's potential as a novel complement to cancer immunotherapy. The FDA's Breakthrough Device Designation reflects recognition of its possible importance for advanced or metastatic cancer patients unresponsive to or intolerant of standard care, as well as for life-threatening viruses without approved treatments. From what I see, this designation can also support more frequent FDA engagement during development.
Long-term value hinges on whether clinical data show that removing extracellular vesicles and viruses improves outcomes. Early observations from the Australian trial, including shifts in immune-related biomarkers, have attracted notice, though the company notes these are preliminary results from an early feasibility study and do not yet confirm clinical benefit. I’m watching this closely as more data emerges.
Risks and Key Considerations
Several material risks warrant attention. As a clinical-stage company, the product lacks approval anywhere, and its safety and efficacy remain unproven. Trials could fail, face delays, or demand more capital than anticipated.
Financially, the company has indicated that existing cash may not cover operations for twelve months, pointing to likely future equity financings that could dilute shareholders. No assurance exists that additional funding will be available on favorable terms.
Additional factors include strong competition in oncology and devices, reliance on regulatory approvals such as from the FDA, dependence on a single platform, and a small team that increases operational concentration. Commercial viability of the Hemopurifier is still unproven, and the company has yet to generate product revenue.
Enhancing Research with AI Tools
In my own analysis, I frequently use Tickeron’s AI Screener to identify and compare stocks like AEMD against industry peers. The platform applies technical indicators, fundamentals, volatility measures, trends, AI signals, and customizable filters to help surface ideas that align with specific strategies. This approach adds discipline to reviewing opportunities in smaller healthcare names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AEMD in +1.46% Uptrend, growing for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AEMD advanced for three days, in 151 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 27 cases where AEMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEMD as a result. In 62 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for AEMD turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 34 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
AEMD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AEMD entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.748) is normal, around the industry mean (4.142). P/E Ratio (-0.373) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.111) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. AEMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
When Do I Have to Withdraw Money from My Roth IRA?
How Does a Health Savings Account Work?
What Are the Fundamentals of Price Action Trading Strategies?
What Are the Different Types of Economies and How Do They Influence Global Dynamics?
Best Human Capital Stock: A Financial Analysis of the Personnel Services Industry
General Information
a provider of diagnostic and therapeutic device solutions for infectious disease, cancer and for other life threatening conditions
Industry MedicalNursingServices
Advertisement